I understand your concern, but you must still recommend vaccines based on current evidence-based guidelines.
Despite personal reservations, as a healthcare provider you have a professional obligation to follow evidence-based guidelines that demonstrate clear mortality and morbidity benefits from vaccination. The most recent and comprehensive guidance from the 2026 ACC Cardiovascular Care guidelines 1 and 2026 AASLD liver transplant guidelines 2 provide clear, specific vaccination schedules that reduce hospitalizations and death.
Core Vaccination Recommendations
Annual Vaccines (Highest Priority for Mortality Reduction)
Influenza:
- One dose yearly for all adults ≥6 months 2, 1, 2
- For adults ≥65 years: Prefer high-dose, recombinant, or adjuvanted formulations 1
- Evidence shows reduced MI, stroke, HF events, and cardiovascular/all-cause mortality 1
COVID-19:
- Updated vaccine annually (current season formulation) 2, 1, 2
- Initial series: 2 doses of Pfizer-BioNTech mRNA OR 2 doses of Moderna mRNA OR 2 doses of Novavax adjuvanted OR 1 dose of Janssen 2
- Followed by booster >2 months after primary series 2
- Reduces severe infection, hospitalization, and mortality 1
One-Time or Series Vaccines
Pneumococcal (Critical for Mortality Reduction):
- Adults ≥50 years: 1 dose of PCV20 or PCV21 (preferred) 1, 3
- Adults 19-64 years with risk conditions: 1 dose of PPSV23 2
- Adults >64 years: 1 dose of PPSV23 at least 1 or 5 years after PCV13 or PPSV23, respectively 2
- Reduces pneumonia, hospitalizations, and death 1
RSV (Respiratory Syncytial Virus):
- Adults ≥50 years: 1 dose (single lifetime dose) 1
- Reduces severe respiratory infections and cardiovascular events 1
Tdap/Td:
Hepatitis B:
- 2-dose Heplisav-B 4 weeks apart (preferred) OR 3-dose Engerix-B, Recombivax-HB, or Twinrix at 0,1, and 6 months 2
Hepatitis A:
- 2 doses of Havrix 6-12 months apart OR Vaqta 6-18 months apart OR 3 doses of Twinrix at 0,1, and 6 months 2
Zoster (Shingles):
- Adults ≥50 years: 2 doses of recombinant zoster vaccine (Shingrix) 2-6 months apart 2, 1, 2
- Emerging evidence shows cardiovascular protection 1
Critical Clinical Considerations
Timing with Immunosuppression:
- Administer ALL vaccines BEFORE starting immunosuppressive therapy whenever possible 5, 6, 7
- Inactivated vaccines can be given during immunosuppression without treatment discontinuation 5, 6
- Live vaccines (MMR, varicella) must be completed 4 weeks prior to transplant or immunosuppression 2
Common Pitfall to Avoid:
- Do NOT delay vaccination waiting for "perfect timing" - the mortality benefit of vaccination far outweighs theoretical concerns about reduced immunogenicity during treatment 5, 7
Evidence for Your Patient Discussion
The 2026 ACC guidelines 1 synthesize four lines of evidence showing:
- Patients with chronic disease face higher risk of severe outcomes from respiratory infections
- Randomized trials demonstrate vaccines reduce severe infection
- Observational studies confirm lower hospitalization and death rates
- Adverse effects from vaccination are exceedingly rare and far outweighed by demonstrated benefits
The professional standard of care requires offering these evidence-based interventions regardless of personal vaccine perspectives. Failure to recommend guideline-concordant vaccination exposes patients to preventable morbidity and mortality.